Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). https://t.co/djn2oTYVtx https://t.co/zmBSXts1LV
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Mentions
Extended reach
Total likes
Video views
Mentions per month
Sep 2022 – Sep 2025Where it's discussed
-
X / Twitter328 posts
-
News53 articles
-
Facebook12 posts
-
Blogs4 articles
-
Bluesky2 posts
-
YouTube2 videos
AI synopsis
What people are saying
Several posts reference the comprehensive nature of the updates, mentioning the shift towards a holistic approach in treatment. For instance, users touched on the importance of physical activity and weight management, using phrases like "game-changing" to signal the report’s transformative potential. The positive and proactive tone prevalent in the discussions underscores the community's collective optimism about the implications of these guidelines.
Many discussions express support for the report's recommendations, highlighting a general consensus on its importance.
The conversations indicate high interest, particularly in the updates regarding managing hyperglycemia and the focus on holistic approaches.
While some posts provide summaries or mention components of the report, most appear to engage at an introductory level rather than deeply analyzing the implications.
Participants perceive the report as having significant influence on diabetes management practices, reflecting a belief in its potential to improve patient outcomes.
Abstract in brief
- The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) updated their consensus on managing hyperglycemia in type 2 diabetes, aimed at health care professionals in the US and Europe.
- New recommendations were influenced by research since 2018, focusing on social determinants of health, healthcare systems, physical activity, and weight management in diabetes care.
- Emphasis is also placed on cardiorenal protection through specific medications, with practical tips for implementation provided alongside the consensus recommendations.
Top posts
Most liked on X and BlueskyGlucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #USMLE #PharmaTwitter #diabeteschat #primarycare #internalmedicine #EndoTwitter #Endocrinology #healthcare #Bioinformatics #healthinformatics #biotech https://t.co/nLXmvaeMZZ
Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endotwitter #internalmedicine #Bioinformatics #healthcare #obesity #MedStudentTwitter #primarycare #Endocrinology #Cardiology #USMLE #TwitteRx #telemedicine https://t.co/tk07Rze56S
Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinology #EndoTwitter #USMLE #internalmedicine #primarycare #diabetes #diabeteschat #PharmaTwitter #healthcare #Bioinformatics #healthinformatics #CardioTwitter https://t.co/iAQ96fdGmu
Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwitter #primarycare #internalmedicine #medstudents #MedicalStudents #TwitteRx #Bioinformatics #eHealth #healthTech #healthcareIT #healthIT @LillyPad #biotech https://t.co/WYtvGq8wOE
Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinology #EndoTwitter #USMLE #internalmedicine #primarycare #diabetes #diabeteschat #PharmaTwitter #Bioinformatics #Health #healthinformatics #CardioTwitter https://t.co/exUJcnZ1cu
All mentions
Impact of Ozempic, Wegovy, and Mounjaro on Body Composition
This video analyzes the impact of Ozempic, Wegovy, and Mounjaro on body composition. These GLP-1 receptor agonists have shown impressive efficacy in weight loss and altering body composition in individuals with type 2…
Essential Health Habits for Longevity and Wellbeing
Want to feel better, think clearer, and live longer? This video outlines a 10-point health checklist that builds a strong foundation for wellbeing. Topics include sleep, nutrition, stress management, and more, with…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
@Mexnexus
RT @cristinatejerap: Just release ▶️ Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Asso…
We thank our guest speaker Dr. Deborah J. Wexler for presenting "Nuances of Management of Hyperglycemia in Type 2 Diabetes: An Evidence-Based Update" at today's Medical Grand Rounds! We hope to see everyone next week!
We invite members of the UMass community to join us today at noon, in person and via Zoom, for our Medical Grand Rounds presentation titled, "Nuances of Management of Hyperglycemia in Type 2 Diabetes: An Evidence-Based Update," featuring Dr. Deborah J. Wexler. We hope to see you there!
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
糖尿病予防・治療に有効なライフスタイルについては、同じアメリカ糖尿病協会の別の資料によくまとまっている。 座位時間の削減、運動、睡眠ごとに推奨事項が記載されている https://t.co/HSJUBt5Hc8 https://t.co/YXNRISjxo6
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @ApoSpecialtyRx: IMPORTANCE OF 24-HR PHYSICAL BEHAVIORS FOR TYPE 2 DIABETES https://t.co/EAIEXGkjNs #SanDiego #SanFrancisco #BeverlyHill…
RT @DiabetesCareADA: ⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report…
RT @DiabetesCareADA: ⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report by the ADA and the European Association for the Study of Diabetes (EASD) -Melanie J. Davies et al. https://t.co/1gfXX82R8U… @ADA_Pubs https://t.co/Cl2pR6ZXl6
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD202…
IMPORTANCE OF 24-HR PHYSICAL BEHAVIORS FOR TYPE 2 DIABETES https://t.co/EAIEXGkjNs #SanDiego #SanFrancisco #BeverlyHills #SantaBarbara #SantaMonica #NewportBeach #Manhattan #SiliconValley #MarinCounty #NewYorkCity #NYC #Mounjaro #Wegovy #LaJolla #Zepbound #Hollywood #Ozempic https://t.co/AuxI1VIcir
RT @ADA_Pubs: ✅Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @DiabetesCareADA: ⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report…
RT @DiabetesCareADA: ⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report…
⭐️Best of #DiabetesCareADA2023⭐️ | #05 ALTMETRIC Management of Hyperglycemia in T2 Diabetes, 2022. A Consensus Report by the ADA and the European Association for the Study of Diabetes (EASD) -Melanie J. Davies et al. https://t.co/1gfXX83oYs… @ADA_Pubs https://t.co/XCwYFaH0cA
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @cardioteca:
RT @EDEN_Leicester: The 5⃣S's came from groundbreaking research from @LDC_tweets and was published: https://t.co/pV106DM2vy We have also d…
RT @EDEN_Leicester: The 5⃣S's came from groundbreaking research from @LDC_tweets and was published: https://t.co/pV106DM2vy We have also d…
The 5⃣S's came from groundbreaking research from @LDC_tweets and was published: https://t.co/pV106DM2vy We have also done a special #MyEden series on the 5S's: https://t.co/bLrZZWon4a
RT @LeslieMegom:
RT @Leo_Santo5: Elección de Medicamentos Hipoglucemiantes en Diabetes tipo 2 por Objetivo y Comorbilidades
8/ The paradigm of #T2D treatment is shifting to a holistic, cardiorenal-metabolic approach. #lipid #CVD
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
RT @scottisaacsmd: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and…
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). https://t.co/djn2oTYVtx https://t.co/zmBSXts1LV
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @DrDosari: صدرت قبل قليل التحديثات الجديدة لعلاج السكري من الجمعية الأوروبية لدراسة السكري بالتعاون مع الجمعية الأمريكية للسكري. #EASD…
RT @Diabetes_SEMI:
RT @DrDosari: صدرت قبل قليل التحديثات الجديدة لعلاج السكري من الجمعية الأوروبية لدراسة السكري بالتعاون مع الجمعية الأمريكية للسكري. #EASD…
@RichardTalbot9 @DrJohnFa @Balthierlord @FZores Sauf que avec les reco européennes du diabète, mono thérapie par metformine n’est plus forcément incontournable https://t.co/93m4gU0X4N
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @Innov_Medicine: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association #EASD20…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocr…
Holistic Person-Centered Approach to Type-2 Diabetes Management (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinology #EndoTwitter #USMLE #internalmedicine #primarycare #diabetes #diabeteschat #PharmaTwitter #Bioinformatics #Health #healthinformatics #CardioTwitter https://t.co/exUJcnZ1cu
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinolog…
Importance of 24-h Physical Behaviors for Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #Endocrinology #EndoTwitter #USMLE #internalmedicine #primarycare #diabetes #diabeteschat #PharmaTwitter #healthcare #Bioinformatics #healthinformatics #CardioTwitter https://t.co/iAQ96fdGmu
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
RT @ApoThera: Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #U…
Glucose-lowering Meds in the Management of Type 2 Diabetes (ADA/EASD) https://t.co/IAtPbgNCus #MedEd #MedTwitter #diabetes #USMLE #PharmaTwitter #diabeteschat #primarycare #internalmedicine #EndoTwitter #Endocrinology #healthcare #Bioinformatics #healthinformatics #biotech https://t.co/nLXmvaeMZZ
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
RT @ApoThera: Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endot…
Use of glucose-lowering medications in the management of type 2 diabetes https://t.co/IAtPbgNCus #MedTwitter #diabetes #Endotwitter #internalmedicine #Bioinformatics #healthcare #obesity #MedStudentTwitter #primarycare #Endocrinology #Cardiology #USMLE #TwitteRx #telemedicine https://t.co/tk07Rze56S
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
RT @ApoThera: Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwit…
Management of Hyperglycemia in Type 2 Diabetes https://t.co/IAtPbgNCus #MedTwitter #MedEd #diabetes #Endocrinology #EndoTwitter #primarycare #internalmedicine #medstudents #MedicalStudents #TwitteRx #Bioinformatics #eHealth #healthTech #healthcareIT #healthIT @LillyPad #biotech https://t.co/WYtvGq8wOE
RT @Leo_Santo5: Elección de Medicamentos Hipoglucemiantes en Diabetes tipo 2 por Objetivo y Comorbilidades
RT @Leo_Santo5: Elección de Medicamentos Hipoglucemiantes en Diabetes tipo 2 por Objetivo y Comorbilidades
2型糖尿病における高血糖管理2022: ASAおよびEASDによるコンセンサスレポート(全文フリー) #ペ読 https://t.co/Te6RmnKILi
Contained in: https://t.co/p0sUt6I59F
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) https://t.co/s4mhIJjxmJ